atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
Sam Altman also said AI could already diagnose better than doctors, as his company expands into Washington. The OpenAI founder then turned to healthcare, making the suggestion that AI’s diagnostic capabilities had surpassed human doctors, but wouldn’t go so far as to accept…
Attendees
Sponsors and Exhibitors
Contact us